AllianceBernstein’s Genocea Biosciences, Inc. GNCA Stock Holding History

AllianceBernstein’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-38	Closed	-$4K	–	3396
2015 Q1	$4K	Hold	38	–	–	﹤0.01%	3446
2014 Q4	$2K	Hold	38	–	–	﹤0.01%	3414
2014 Q3	$3K	Sell	38 -37	-49%	-$4.05K	﹤0.01%	3380
2014 Q2	$11K	Buy	+75	New	+$11.4K	﹤0.01%	3302

Other funds holding GNCA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein's GNCA Position: Q2 2015 in Review

AllianceBernstein sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2015, closing a stake of 38 shares — an estimated $4K sold.

AllianceBernstein first reported a position in GNCA in Q2 2014 and held it in 4 quarters. The position peaked at $11K in Q2 2014. 60 funds tracked by Wall St. Rank hold GNCA as of Q2 2015.

AllianceBernstein reported no remaining Genocea Biosciences, Inc. position as of Q2 2015 after selling out during the quarter.
AllianceBernstein sold 38 Genocea Biosciences, Inc. shares in Q2 2015, an estimated $4K.
AllianceBernstein first reported a position in Genocea Biosciences, Inc. in Q2 2014 and held it in 4 quarters.
AllianceBernstein's Genocea Biosciences, Inc. position peaked at $11K in Q2 2014.
60 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2015.

Based on AllianceBernstein's 13F filing for Q2 2015, filed 14 Aug 2015.